Director/PDMR Shareholding
March 13, 2017 – Shire plc
(LSE: SHP, NASDAQ: SHPG) (the “Company”)
Notification of transactions by
persons discharging managerial responsibilities
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
a) |
Name |
Flemming Ornskov |
2. |
Reason for the
notification |
a) |
Position / status |
Chief Executive Officer
- PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of Restricted
Stock Units (“RSUs”) in respect of notional ADSs awarded under the
Shire Deferred Bonus Plan 2015 as part of the Executive Annual
Incentive. The RSUs will vest on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
3,721 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
N/A |
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
a) |
Name |
Jeffrey Poulton |
2. |
Reason for the
notification |
a) |
Position / status |
Chief Financial Officer
- PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of Restricted
Stock Units (“RSUs”) in respect of notional ADSs awarded under the
Shire Deferred Bonus Plan 2015 as part of the Executive Annual
Incentive. The RSUs will vest on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
1,160 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
N/A |
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
a) |
Name |
Bill Mordan |
2. |
Reason for the
notification |
a) |
Position / status |
General Counsel and
Company Secretary – PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of Restricted
Stock Units (“RSUs”) in respect of notional ADSs awarded under the
Shire Deferred Bonus Plan 2015 as part of the Executive Annual
Incentive. The RSUs will vest on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
859 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
N/A |
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
a) |
Name |
Perry Sternberg |
2. |
Reason for the
notification |
a) |
Position / status |
Head of US Commercial -
PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of ADSs,
acquired as Restricted Stock (“RS”) pursuant to the Shire Deferred
Bonus Plan 2015, as part of the Executive Annual Incentive. The
restrictions applying to the RS will cease on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
$177.98 |
100 |
$177.87 |
100 |
$177.99 |
100 |
d) |
Aggregated
information |
Weighted average price |
Volume |
$177.95 |
300 |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
NSDQ |
5. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of ADSs,
acquired as Restricted Stock (“RS”) pursuant to the Shire Deferred
Bonus Plan 2015, as part of the Executive Annual Incentive. The
restrictions applying to the RS will cease on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
$177.86 |
100 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
BATS |
6. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of ADSs,
acquired as Restricted Stock (“RS”) pursuant to the Shire Deferred
Bonus Plan 2015, as part of the Executive Annual Incentive. The
restrictions applying to the RS will cease on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
$177.87 |
100 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
NQPX |
7. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of ADSs,
acquired as Restricted Stock (“RS”) pursuant to the Shire Deferred
Bonus Plan 2015, as part of the Executive Annual Incentive. The
restrictions applying to the RS will cease on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
$177.84 |
30 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
XEDGX |
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
a) |
Name |
Kim Stratton |
2. |
Reason for the
notification |
a) |
Position / status |
Head of International
Commercial - PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc Ordinary Shares of 5 pence each (“Ordinary
Shares”)
|
Identification
code |
ISIN:
JE00B2QKY057 |
b) |
Nature of the transaction |
Receipt of Restricted
Stock Units (“RSUs”) in respect of notional Ordinary Shares awarded
under the Shire Deferred Bonus Plan 2015 as part of the Executive
Annual Incentive. The RSUs will vest on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
2,923 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
N/A |
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
a) |
Name |
Philip Vickers |
2. |
Reason for the
notification |
a) |
Position / status |
Head of Research and
Development – PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of Restricted
Stock Units (“RSUs”) in respect of notional ADSs awarded under the
Shire Deferred Bonus Plan 2015 as part of the Executive Annual
Incentive. The RSUs will vest on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
844 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
N/A |
1. |
Details
of the person discharging managerial responsibilities (“PDMR”) /
person closely associated them (“PCA”) |
a) |
Name |
Matt Walker |
2. |
Reason for the
notification |
a) |
Position / status |
Head of Technical
Operations – PDMR |
b) |
Initial notification /
amendment |
Initial
notification |
3. |
Details of the
issuer, emission allowance participant, auction platform,
auctioneer or auction monitor |
a) |
Name |
Shire plc |
b) |
LEI |
54930005LQRLI2UXRQ59 |
4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
a) |
Description of the
financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
|
Identification
code |
ISIN:
US82481R1068 |
b) |
Nature of the transaction |
Receipt of Restricted
Stock Units (“RSUs”) in respect of notional ADSs awarded under the
Shire Deferred Bonus Plan 2015 as part of the Executive Annual
Incentive. The RSUs will vest on March 10, 2020. |
c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
N/A |
414 |
d) |
Aggregated
information |
N/A
(single transaction) |
e) |
Date of the transaction |
March 10, 2017 |
f) |
Place of the transaction |
N/A |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please
contact:
Investor
Relations |
|
|
Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
Media |
|
|
Lisa Adler |
lisa.adler@shire.com |
+1 617
588 8607 |
Debbi Ford |
debbi.ford@shire.com |
+1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases. We strive to develop
best-in-class products, many of which are available in more than
100 countries, across core therapeutic areas including Hematology,
Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com